THE PATHOLOGY OF MELANOMA:

AN INTERNATIONAL COURSE

APRIL 11 & 12, 2024

// OBJECTIVE

Following the success of our Courses in 2017, 2018, 2020, and 2022 the objective of the Fifth International Melanoma Course in 2024 will continue to stress due diligence and practical diagnosis of melanocytic lesions. We will emphasize the theme of “Acknowledging uncertainty and avoiding over diagnosis of melanoma”, as well as updates of all cutting-edge knowledge on difficult melanocytes lesions relevant to practicing pathologists and clinicians.

This 2024 venue will again include expertise from the SIRIC (Integrated Cancer Research Site at Institut Curie), the WHO 5th Edition Classification of Melanocytic Tumours, the revised MPATH-Dx Classification schema (2023), the MPATH Group, and the International Melanoma Pathology Study Group.

// THE REVISED MPATH-Dx CLASSIFICATION

  • The revised MPATH (Version 2.0) schema provides a simplified two category system for benign melanocytic lesions: Class I. Low-grade and Class II. High-grade lesions. Practical criteria allow for the mapping of all benign melanocytic lesions with diverse terminologies into these categories.
  • The classification of melanoma is refined by the recognition of a low-risk category of T1a melanoma in the new Class III.
  • The schema provides estimates of risk for disease progression and guidelines for practical management.

// THE COURSE PROGRAMME AND CONTENT

  • The Course will consist of didactic lectures and interactive sessions during the two-day program.
  • An approach of practical diagnosis is based on the extensive experience of the international faculty in the Course.
  • The latest advances in ancillary diagnostic techniques including immunohistochemistry and molecular genetics will be emphasized.
  • Particular attention will be given to predictive biomarkers for targeted, immune and checkpoint inhibitors therapies.

List of speakers

Directors

Course Director

Pr Raymond L. Barnhill

Pr

Boris Bastian

Pr

Klaus Busam

Pr

David Elder

Pr

Richard Scolyer

Course Director

Pr Raymond L. Barnhill

Director of the course

Raymond L. Barnhill is currently Professor of Pathology at the Institut Curie, and the Faculty of Medicine, University of Paris Descartes, Paris, France. Dr. Barnhill received his MD degree from Duke University and was a postdoctoral fellow and graduate student in the University of Oxford. He has trained as a dermatologist, anatomic pathologist, and dermatopathologist.

His academic and research interests have largely been associated with the biology of melanocytic lesions and melanoma, but also all aspects of dermatopathology and more recently ophthalmic pathology. He has held major academic leadership appointments including Director of Dermatopathology at Brigham and Women’s Hospital and Children’s Hospital, Harvard Medical School, and Director of Dermatopathology (tenured professor) at Johns Hopkins University. Pr Barnhill has founded both the North American Melanoma Pathology Study Group and in 2007 the International Melanoma Pathology Study Group, of which he is currently President.

He has also been an active member of the WHO Melanoma Program and the EORTC Melanoma Group and many other professional societies. In 2011, he received the Founder’s Award from the American Society of Dermatopathology. Pr Barnhill is the author of a substantial number of original articles, chapters and reviews, and the author, co-author, or editor of five books, including three leading textbooks in dermatopathology and the pathology of melanoma.

Pr

Boris Bastian

Dr. Boris Bastian received his MD degree and Dr. med degree from the Ludwig-Maximilian University of Munich. After completing a residency in dermatology at the University of Wurzburg, he received additional training in dermatopathology and completed a postdoctoral fellowship at the University of California, San Francisco before joining the institution’s faculty and starting his research laboratory at UCSF’s Helen Diller Family Comprehensive Cancer Center. In 2010 he moved to the Memorial Sloan-Kettering Cancer Center to become Chairman of the Department of Pathology. In 2011 he returned to UCSF where he holds the title of Gerson and Barbara Bakar Distinguished Professor of Cancer Biology. He founded and directs the Clinical Cancer Genomics Laboratory at UCSF, which performs molecular diagnostics for patients of the Helen Diller Family Comprehensive Cancer Center. He has clinical responsibilities in the Dermatopathology Section of the Departments of Dermatology and Pathology, where he also oversees the molecular diagnostic laboratory.

Dr. Bastian’s research laboratory focuses on the molecular genetics of cutaneous neoplasms, with a particular emphasis on the discovery of genetic alterations useful for diagnosis, classification, and therapy. His laboratory has contributed to the discovery of several genetic alterations in melanocytic neoplasia that are relevant for therapeutic and diagnostic purposes and to the current WHO classification of melanocytic neoplasms. He served as the President of the Society of Melanoma Research from 2010 to 2013. He has received numerous awards for his work including the election to the German National Academy of Sciences, the Lila Gruber Award for Cancer Research of the American Academy of Dermatology, and an Outstanding Investigator Award of the National Cancer Institute. .

Pr

Klaus Busam

Current position:
Professor of Pathology and Laboratory Medicine
Weill Medical College of Cornell University
Director of Dermatopathology and Director of Immunohistochemistry
Department of Pathology, Memorial Sloan Kettering Cancer Center
1275 York Ave, New York, NY 10065

Training:
Medical school – University of Freiburg, Germany
Postdoctoral research at NCI/NIH
Residency in Anatomic Pathology and Brigham and Women’s Hospital
Fellowship in Dermatopathology under Dr. Barnhill

Pr

David Elder

David Elder is Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, which is the oldest teaching hospital in the United States. He trained in New Zealand at the University of Otago with John Blennerhassett MD, and with Vincent McGovern, MD of the Sydney Melanoma Unit in Australia. He then moved to Philadelphia, initially with Wallace H Clark Jr., MD at Temple University and then at the University of Pennsylvania where Ted Enterline, MD was Director of Anatomic Pathology and a strong influence. Dr Elder was Vice Chair and Director for Anatomic Pathology in the Department of Pathology and Laboratory Medicine from 1999 through 2011, and currently leads its Dermatopathology Program within the Section of Surgical Pathology.

In 2004 he was made a Distinguished Fellow of the Royal College of Pathologists of Australasia and in 2011 he was honored with a Life Membership of the British Society for Dermatopathology. He is a founding member of the Penn Melanoma and Pigmented Lesion Study Group (founded by Wallace Clark) since 1978, leading its pathology component for many of these years. During this time, this group described dysplastic nevi, and defined the radial and vertical growth phases of melanoma. In other studies, prognostic models for melanoma were developed, using histopathologic and other markers. These have included proliferation markers, and markers of the tumor host response. The group has also been closely involved with the development of new targeted therapies and of immunotherapy for melanoma.

Dr. Elder has also been a leading member of the Melanoma Genetics Consortium (Genomel), serving as Principal Investigator of an NIH grant supporting this program for 10 years. This group has defined the biology of genes that convey risk for the development of melanoma in Europe, Australia and the Americas. Dr. Elder has published over 200 peer-reviewed scientific articles and reviews, mostly in the field of melanoma and related conditions. In addition, he has authored or edited several textbooks, including the 3rd and 4th series US Armed Forces Institute of Pathology Fascicles on Melanocytic Tumors of the Skin, and the latest four editions of “Lever’s Histopathology of the Skin”. Other publications include the Atlas and Synopsis of Lever’s Histopathology of the Skin which is in its 3rd Edition and presents a unified pattern classification system for inflammatory and neoplastic skin diseases, complementing the “Big Lever”.

He has also edited a series of monographs called Consultant Pathology, and is currently serving as the Lead Editor for the latest revision of the WHO “Blue Book” on classification of skin neoplasms. Dr Elder continues to pursue his interests in the classification and diagnosis of skin disease and in particular the diagnosis and prognosis of melanoma and other melanocytic tumors, and regularly participates in the clinical activities of his specialty at Penn.

Pr

Richard Scolyer

Conjoint Medical Director, Melanoma Institute Australia
Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney
Clinical Professor, Sydney Medical School, The University of Sydney
National Health and Medical Research Council Practitioner Fellow

Richard Scolyer studied medicine at the University of Tasmania (BMedSci, MBBS). After completing clinical training in Australia and overseas, he undertook pathology training at the Canberra Hospital and at the Royal Prince Alfred Hospital leading to Fellowship of the Royal College of Pathologists of Australasia. Richard is currently Consultant Pathologist and Co-Director of Research, Melanoma Institute Australia; Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; and Clinical Professor, The University of Sydney.

Richard has presented on more than 150 occasions at conferences throughout the world, and is a co- author of more than 400 articles and book chapters on melanocytic pathology and related research. In 2006, Richard was awarded the degree of Doctor of Medicine by The University of Sydney for his thesis of publications on melanocytic pathology. He received a NSW Premier’s Award for Outstanding Cancer Research in 2009 and 2012 and the Thomson Reuters 2015 Citation Award in the Clinical Medicine category. Richard is Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of their Cancer Staging System, an editorial board member of the American Journal of Surgical Pathology, a member of the International Editorial Advisory Board of Histopathology and Senior Associate Editor of Pathology. Richard is currently President of the Australasian Division of the International Academy of Pathology. Together with other MIA colleagues, Richard is chief investigator on a 5 year NHMRC program grant and has a personal Fellowship from the NHMRC.

Director of the course
Director
Director
Director
Director

LIST OF SPEAKERS

Pr Raymond Barnhill,
Institut Curie and University
of Paris Cité, Paris, France,
Director of the Course

Pr Boris Bastian,
University of California
San Francisco, USA

Pr Klaus Busam,
Memorial Sloan Kettering
Cancer Center, New York, USA

Pr David Elder,
University of Pennsylvania,
Philadelphia, USA

Pr Richard Scolyer,
Melanoma Institute of Australia
and the University of Sydney,
Sydney, Australia

Dr Claire Lugassy,
Institut Curie, Paris, France

Dr Alexandre Matet,
Institut Curie and University
of Paris Cité, Paris, France

Dr Denis Malaise,
Institut Curie, Paris, France

Pr Lori Lowe,
University of Michigan, Ann Arbor, USA

Dr Arnaud de la Fouchardière,
Centre Léon Bérard, Lyon, France

NON EXHAUSTIVE LIST OF TOPICS